Author details

Full Name

Yongmei Chen

Affiliation

ORCID

Career Start Year

2007

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37289194	Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.		2023
35292633	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes.	Nat Commun	2022
35638719	Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990-2017.	Cancer Med	2022
35490227	Machine learning algorithms to estimate 10-Year survival in patients with bone metastases due to prostate cancer: toward a disease-specific survival estimation tool.	BMC Cancer	2022
35354846	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.	Sci Rep	2022
36551611	Co-Mutation Status Association with Clinical Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer.		2022
32967771	Prognostic features of Annexin A2 expression in prostate cancer.	Pathology	2021
34003011	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.	J Urol	2021
33866796	Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with exon 19 deletions or exon 21 mutations.	Future Oncology	2021
32341752	Association of germline genetic variants with <i>TMPRSS2-ERG</i> fusion status in prostate cancer.	Oncotarget	2020
32429558	Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.	Cancers (Basel)	2020
31965751	Race, tumor location, and disease progression among low-risk prostate cancer patients.	Cancer Medicine	2020
31910880	Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.	J Transl Med	2020
31530439	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.	Clin Genitourin Cancer	2019
31741711	Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies <i>ERG</i> as the strongest independent predictor of recurrence.	Oncotarget	2019
31842254	Analysis of <i>PMEPA1</i> Isoforms (<i>a</i> and <i>b</i>) as Selective Inhibitors of Androgen and TGF-Î² Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer.	Cancers (Basel)	2019
30542053	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.	Prostate Cancer Prostatic Dis	2019
30050933	Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy.	BioMed Research International	2018
28753864	Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.	Eur Urol Focus	2018
28410987	Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.	Urologic Oncology: Seminars and Original Investigations	2017
28191285	Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.	Genes Cancer	2016
25200804	Testosterone recovery after polytrauma and scrotal injury in patients from Operation Enduring Freedom and Operation Iraqi Freedom.	Journal of Urology	2015
25465337	A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.	Eur Urol	2015
25344575	ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.	Mol Cancer Res	2015
26844274	A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.	EBioMedicine	2015
24694733	Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.	Epigenetics	2014
25279185	Predominance of ERG-negative high-grade prostate cancers in African American men.	Mol Clin Oncol	2014
24115221	Evaluation of ERG responsive proteome in prostate cancer.	Prostate	2014
25221645	Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.	Genes Cancer	2014
24929891	Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.	Urologic Oncology: Seminars and Original Investigations	2014
21872499	Low risk prostate cancer in men â¿¥ 70 years old: to treat or not to treat.	Urologic Oncology: Seminars and Original Investigations	2013
21826727	Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database.	Neurourology and Urodynamics	2012
22529743	The burden of prostate cancer in Asian nations.	Journal of Carcinogenesis	2012
22950997	Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.	Urology	2012
22096650	Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort.	Prostate Cancer	2011
21397300	Prostate cancer in men less than the age of 50: a comparison of race and outcomes.	Urology	2011
21040364	Prostate cancer in Asian Americans: incidence, management and outcomes in an equal access healthcare system.	BJU International	2011
21074211	Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.	Journal of Urology	2011
21060327	Prostate cancer gene expression signature of patients with high body mass index.	Prostate Cancer Prostatic Dis	2011
21178489	ERG oncogene modulates prostaglandin signaling in prostate cancer cells.	Cancer Biol Ther	2011
21091976	Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.	BJU Int	2011
20160063	Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.	Clin Cancer Res	2010
19117774	Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7.	Urologic Oncology: Seminars and Original Investigations	2010
19597533	Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.	Prostate Cancer Prostatic Dis	2010
19836800	Clinicopathological behavior of single focus prostate adenocarcinoma.	Journal of Urology	2009
19549893	Evaluation of the 8q24 prostate cancer risk locus and MYC expression.	Cancer Res	2009
18065961	Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.	Mod Pathol	2008
18801539	PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.	J Urol	2008
18245536	Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.	Clin Cancer Res	2008
18676740	Delineation of TMPRSS2-ERG splice variants in prostate cancer.	Clin Cancer Res	2008